Physiologically Based Pharmacokinetic Modeling

Preclinical Development Handbook: ADME and Biopharmaceutical Properties

Volumn , Issue , 2008, Pages 1167-1227

  Clewell, Harvey J ^a   Reddy, Micaela B ^b   Lave, Thierry ^c   Andersen, Melvin E ^a  

^a HAMNER INSTITUTES FOR HEALTH SCIENCES   (United States)

^b ROCHE BIOSCIENCE   (United States)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Moncompartmental analysis (NCA); Physicochemical and biochemical parameters; Single dose PK (SDPK) data and PK data

Indexed keywords

EID: 84952713729     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470249031.ch35     Document Type: Chapter

References (113)

1. Teorell T. Kinetics of distribution of substances administered to the body. I. The extravascular mode of administration. Arch Int Pharmacodyn 1937;57:205-225.
2. Teorell T. Kinetics of distribution of substances administered to the body. I. The intravascular mode of administration. Arch Int Pharmacodyn 1937;57:226-240.
3. Andersen ME. Saturable metabolism and its relation to toxicity. Crit Rev Toxicol 1981;9:105-150.
4. Bischoff KB, Brown RG. Drug distribution in mammals. Chem Eng Prog Symp Ser 1966;62(66):33-45.
5. Bischoff KB, Dedrick RL, Zaharko DS, Longstreth JA. Methotrexate pharmacokinetics. J Pharm Sci 1971;60:1128-1133.
6. Collins JM, Dedrick RL, Flessner MF, Guarino AM. Concentration dependent disappearance of fluorouracil from peritoneal fluid in the rat:experimental observations and distributed modeling. J Pharm Sci 1982;71:735-738.
7. Farris FF, Dedrick RL, King FG. Cisplatin pharmacokinetics:applications of a physiological model. Toxicol Lett 1988;43:117-137.
8. Andersen ME, Yang RSH, Clewell HJ, Reddy MB. Introduction:a historical perspective of the development and application of PBPK models. In Reddy MB, Yang RSH, Clewell HJ III, Andersen ME, Eds. Physiologically Based Pharmacokinetic Modeling:Science and Applications. Hoboken, NJ:John Wiley & Sons; 2005, pp 1-18.
9. McMullin TS. Drugs. In Reddy MB, Yang RSH, Clewell HJ III, Andersen ME, Eds. Physiologically Based Pharmacokinetic Modeling:Science and Applications. Hoboken, NJ:John Wiley & Sons; 2005, pp 273-296.
10. Pott O'Brien W. Antineoplastic agents. In Reddy MB, Yates RSH, Clewell HJ III, Andersen ME, Eds. Physiologically Based Pharmacokinetic Modeling:Science and Applications. Hoboken, NJ:John Wiley Sons; 2005, pp 297-317.
11. Lupfert C, Reichel A. Development and application of physiologically based pharmacokinetic-modeling tools to support drug discovery. Chem Biodiversity 2005;2:1462-1486.
12. Nestorov I. Whole body pharmacokinetic models. Clin Pharmacokinet 2003;42:883-908.
13. Jones HM, Parrott N, Jorga K, Lave T. A novel strategy for physiologically based predictions of human pharmacokinetics. Clin Pharmacokinet 2006;45:511-542.
14. Parrott N, Jones H, Paquereau N, Lavé T. Application of full physiological models for pharmaceutical drug candidate selection and extrapolation of pharmacokinetics to man. Basic Clin Pharmacol Toxicol 2005;96:193-199.
15. Baxter LT, Zhu H, Mackensen DG, Jain RK. Physiologically-based pharmacokinetic model for specific and nonspecific monoclonal-antibodies and fragments in normal-tissues and human tumor xenografts in nude-mice. Cancer Res 1994;54:1517-1528.
16. Baxter LT, Zhu H, Mackensen DG, Butler WF, Jain RK. Biodistribution of monoclonal-antibodies-scale-up from mouse to human using a physiologically-based pharmacokinetic model. Cancer Res 1995;55:4611-4622.
17. Aarons L. Editors'view. Physiologically based pharmacokinetic modeling:a sound mechanistic basis is needed. Br J Clin Pharm 2005;60(6):581-583.
18. Dedrick RL, Bischoff KB. Species similarities in pharmacokinetics. Fed Proc 1980;39:54-59.
19. Clewell HJ, Andersen ME, Wills RJ, Latriano L. A physiologically based pharmacokinetic model for retinoic acid and its metabolites. J Am Acad Dermatol 1997;36:S77-S85.
20. Reddy MB, Yang RSH, Clewell HJ III, Andersen ME, Eds. Physiologically Based Pharmacokinetic Modeling:Science and Applications. Hoboken, NJ:John Wiley & Sons; 2005.
21. Brightman FA, Leahy DE, Searle GE, Thomas S. Application of a generic physiologically based pharmacokinetic model to the estimation of xenobiotic levels in rat plasma. Drug Metab Dispos 2006;34:84-93.
22. Brightman FA, Leahy DE, Searle GE, Thomas S. Application of a generic physiologically based pharmacokinetic model to the estimation of xenobiotic levels in human plasma. Drug Metab Dispos 2006;34:94-101.
23. Malaty LI, Kuper JJ. Drug interactions of HIV. Protease inhibitors. D rug Safety 1999;20:147-169.
24. Adolph EF. Quantitative relations in the physiological constitutions of mammals. Science 1949;109:579-585.
25. Dedrick RL. Animal scale-up. J Pharmacokinet Biopharm 1973;1:435-461.
26. Astrand P, Rodahl K. Textbook of Work Physiology. New York:McGraw-Hill; 1970, pp 157-160, 206-211.
27. International Commission on Radiological Protection (ICRP). Report of the Task Group on Reference Man. ICRP Publication 23; 1975, pp 228-237, 280-285, 325-327.
28. Environmental Protection Agency (EPA). Reference physiological parameters in pharmacokinetic modeling. EPA/600/6-88/004. Washington, DC:Office of Health and Environmental Assessment; 1988.
29. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res 1993;10:1093-1095.
30. Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, Beliles RP. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Indust Health 1997;13(4):407-484.
31. Jepson GW, Hoover DK, Black RK, McCafferty JD, Mahle DA, Gearhart JM. A partition coefficient determination method for nonvolatile chemicals in biological tissues. Fundam Appl Toxicol 1994;22:519-524.
32. Clewell HJ. Coupling of computer modeling with in vitro methodologies to reduce animal usage in toxicity testing. Toxicol Lett 1993;68:101-117.
33. Yates FE. Good manners in good modeling:mathematical models and computer simulations of physiological systems. Am J Physiol 1978;234:R159-R160.
34. Carson ER, Cobelli C, Finkelstein L. The Mathematical Modeling of Metabolic and Endocrine Systems. Model Formulation, Identification, and Validation. Hoboken, NJ:John Wiley & Sons; 1983, pp 23-45, 113-127, 217-231.
35. Rescigno A, Beck JS. Perspectives in pharmacokinetics. The use and abuse of models. J Pharmacokinet Biopharm 1987;15(3):327-344.
36. Himmelstein KJ, Lutz RJ. A review of the application of physiologically based pharmacokinetic modeling. J Pharmacokinet Biopharm 1979;7:127-145.
37. Gerlowski LE, Jain RK. Physiologically based pharmacokinetic modeling:principles and applications. J Pharm Sci 1983;72:1103-1126.
38. Nestorov IA, Aarons LJ, Arundel PA, Rowland M. Lumping of whole-body physiologically based pharmacokinetic models. J Pharmacokinet Biopharm 1998;26(1):21-46.
39. Clewell HJ, Lee T, Carpenter RL. Sensitivity of physiologically based pharmacokinetic models to variation in model parameters:methylene chloride. Risk Anal 1994;14:521-531.
40. Campain J. Metals and inorganic compounds. In Reddy MB, Yang RSH, Clewell HJ III, Andersen ME, Eds. Physiologically Based Pharmacokinetic Modeling:Science and Applications. Hoboken, NJ:John Wiley & Sons; 2005, pp 239-270.
41. Lin JH. Applications and limitations of interspecies scaling and in vitro extrapolation in pharmacokinetics. Drug Metab Dispos 1998;26:1202-1212.
42. Hinderling PH. Red blood cells:a neglected compartment in pharmacokinetics and pharmacodynamics. Pharmacol Rev 1997;49:279-295.
43. Andersen ME, Clewell HJ, Gargas ML, Smith FA, Reitz RH. Physiologically-based pharmacokinetics and the risk assessment for methylene chloride. Toxicol Appl Pharmacol 1987;87:185-205.
44. Agoram B, Woltosz WS, Bolger MB. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv Drug Deliv Rev 2001;50(Suppl 1):S41-S67.
45. Willmann S, Schmitt W, Keldenich J, Dressman JB. A physiologic model for simulating gastrointestinal flow and drug absorption in rats. Pharm Res 2003;20:1766-1771.
46. Semino G, Lilly P, Andersen ME. A pharmacokinetic model describing pulsatile uptake of orally-administered carbon tetrachloride. Toxicology 1997;117(1):25-33.
47. Chaturvedi PR, Decker CJ, Odinecs A. Prediction of pharmacokinetic properties using experimental approaches during early drug discovery. Curr Opin Chem Biol 2001;5(4):452-463.
48. Cai H, Stoner C, Reddy A, Freiwald S, Smith D, Winters R, Stankovic C, Surendran N. Evaluation of an integrated in vitro-in silico PBPK(physiologically based pharmacokinetic) model to provide estimates of human bioavailability. Int J Pharm 2006;308 (1-2):133-139.
49. Dennison JE, Andersen ME. Reactive vapors in the nasal cavity. In Reddy MB, Yang RSH, Clewell HJ III, Andersen ME, Eds. Physiologically Based Pharmacokinetic Modeling:Science and Applications. Hoboken, NJ:John Wiley & Sons; 2005, pp 375-387.
50. Reddy MB. PBPK modeling approaches for special applications:dermal exposure models. In Reddy MB, Yang RSH, Clewell HJ III, Andersen ME, Eds. Physiologically Based Pharmacokinetic Modeling:Science and Applications. Hoboken, NJ:John Wiley & Sons; 2005, pp 375-387.
51. McCarley KD, Bunge AL. Pharmacokinetic models of dermal absorption. J Pharm Sci 2001;90(11):1699-1719.
52. Roberts MS, Anissimov YG, Gonsalvez RA. Mathematical models in percutaneous absorption (Reprinted from Percutaneous Adsorption 1999;3-55). J Toxicol-Cutaneous Ocular Toxicol 2001;20:221-270.
53. Andersen ME, Mills JJ, Gargas ML, Kedderis L, Birnbaum LS, Neubert D, Greenlee WF. Modeling receptor-mediated processes with dioxin:implications for pharmacokinetics and risk assessment. Risk Anal 1993;13(1):25-36.
54. Kohn MC, Lucier GW, Clark GC, Sewall C, Tritscher AM, Portier CJ. A mechanistic model of effects of dioxin on gene expression in the rat liver. Toxicol Appl Pharmacol 1993;120(1):138-154.
55. Plowchalk DR, Teeguarden J. Development of a physiologically based pharmacokinetic model for estradiol in rats and humans:a biologically motivated quantitative framework for evaluating responses to estradiol and other endocrine-active compounds. Toxicol Sci 2002;69(1):60-78.
56. Mendel CM. The free hormone hypothesis:distinction from the free hormone transport hypothesis. J Androl 1992;13(2):107-116.
57. Lam G, Chen M, Chiou WL. Determination of tissue to blood partition coefficients in physiologically-based pharmacokinetic studies. J Pharm Sci 1982;71(4):454-456.
58. Lin JH, Sugiyama Y, Awazu S, Hanano M. In vitro and in vivo evaluation of the tissue-to-blood partition coefficients for physiological pharmacokinetic models. J Pharmacokinet Biopharm 1982;10(6):637-647.
59. Pelekis M, Poulin P, Krishnan K. An approach for incorporating tissue composition data into physiologically based pharmacokinetic models. Toxicol Ind Health 1995;11:511-522.
60. Poulin P, Krishnan K. A biologically-based algorithm for predicting human tissue-blood partition coefficients of organic chemicals. Hum Exp Toxicol 1995;14:273-280.
61. Poulin P, Krishnan K. An algorithm for predicting tissue:blood partition coefficients of organic chemicals from n-octanol:water partition coefficient data. J Toxicol Environ Health 1995;46:117-129.
62. Poulin P, Theil FP. A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. J Pharm Sci 2000;89:16-35.
63. Poulin P, Theil F. Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J Pharm Sci 2002;91:129-156.
64. Rodgers T, Leahy D, Rowland M. Physiologically based pharmacokinetic modeling 1:Predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci 2005;94:1259-1276.
65. Rodgers T, Rowland M. Physiologically based pharmacokinetic modelling 2:Predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 2006;95:1238-1257.
66. Zuegge J, Schneider G, Coassolo P, Lavé T. Prediction of hepatic metabolic clearance-comparison and assessment of prediction models. Clin Pharmacokinet 2001;40:553-563.
67. Lavé T, Coassolo P, Reigner B. Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and in vitro in vivo correlations. Clin Pharmacokinet 1999;36:211-231.
68. Houston JB. Relevance of in-vitro kinetic-parameters to in-vivo metabolism of xenobiotics. Toxicol In Vitro 1994;8:507-512.
69. Houston JB, Carlile DJ. Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. Drug Metab Rev 1997;29:891-922.
70. Obach RS. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data:an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 1999;27:1350-1359.
71. Ito K, Iwatsubo T, Kanamitsu S, Nakajima Y, Sugiyama Y. Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. Annu Rev Pharmacol Toxicol 1998;38:461-499.
72. Barter ZE, Bayliss MK, Beaune PH, Boobis AR, Carlile DJ, Edwards RJ, Houston JB, Lake BG, Lipscomb JC, Pelkonen OR, Tucker GT, Rostami-Hodjegan A. Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data:reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr Drug Metab 2007;8:33-45.
73. Reddy MB, Andersen ME, Morrow PE, Dobrev ID, Varaprath S, Plotzke KP, Utell MJ. Physiological modeling of inhalation kinetics of octamethylcyclotetrasiloxane in humans during rest and exercise. Toxicol Sci 2003;72:3-18.
74. Blau GE, Neely WB. Dealing with uncertainty in pharmacokinetic models using SIMUSOLV. In Drinking Water and Health, Vol. 8. Washington, DC:National Research Council; 1987, pp 185-207.
75. Cobelli C, Carson ER, Finkelstein L, Leaning MS. Validation of simple and complex models in physiology and medicine. Am J Physiol 1984;246:R259-R266.
76. Gueorguieva I, Nestorov IA, Rowland M. Reducing whole body physiologically based pharmacokinetic models using global sensitivity analysis:diazepam case study. J Pharmacokinet Pharmacodyn 2006;33(1):1-27.
77. Clewell HJ. The use of physiologically based pharmacokinetic modeling in risk assessment:a case study with methylene chloride. In Olin S, Farland W, Park C, Rhomberg R, Scheuplein L, Starr T, Wilson J, Eds. Low-Dose Extrapolation of Cancer Risks:Issues and Perspectives. Washington, DC:ILSI Press; 1995.
78. Clewell HJ, Andersen ME. Use of physiologically-based pharmacokinetic modeling to investigate individual versus population risk. Toxicology 1996;111:315-329.
79. Parrott N, Paquereau N, Coassolo P, Lavé T. An evaluation of the utility of physiologically based models of pharmacokinetics in early drug discovery. J Pharm Sci 2005;94:2327-2343.
80. Parrott N, Lavé T. Prediction of intestinal absorption:comparative assessment of GASTROPLUS (TM) and IDEA (TM). Eur J Pharm Sci 2002;17:51-61.
81. Tucker GT, Houston JB, Huang SM. Optimizing drug development:strategies to assess drug metabolism/transporter interaction potential-toward a consensus. Pharm Res 2001;18:1071-1080.
82. Telgmann R, von Kleist M, Huisinga W. Software supported modelling in pharmacokinetics. CompLife 2006;216-225.
83. Leahy DE. Integrating in vitro ADMET data through generic physiologically based pharmacokinetic models. Expert Opin Drug Metab Toxicol 2006;2:619-628.
84. Lavé T, Dupin S, Schmitt C, Valles B, Ubeaud G, Chou RC, Jaeck D, Coassolo P. The use of human hepatocytes to select compounds based on their expected hepatic extraction ratios in humans. Pharm Res 1997;14:152-155.
85. Thompson TN. Early ADME in support of drug discovery:the role of metabolic stability studies. Curr Drug Metab 2000;1:215-241.
86. Poggesi I. Predicting human pharmacokinetics from preclinical data. Curr Opin Drug Discov Dev 2004;7:100-111.
87. Riley RJ, McGinnity DF, Austin RP. A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metab Dispos 2005;33:1304-1311.
88. Poulin P, Theil FP. Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition. J Pharm Sci 2002;91:1358-1370.
89. Reigner BG, Blesch KS. Estimating the starting dose for entry into humans:principles and practice. Eur J Clin Pharmacol 2002;57:835-845.
90. Luttringer O, Theil F-P, Poulin P, Schmitt-Hoffmann AH, Guentert TW, Lavé T. Physiologically based pharmacokinetic (PBPK) modeling of disposition of epiroprim in humans. J Pharm Sci 2003;92:1990-2007.
91. Bischoff KB, Dedrick RL, Zaharko DS. Preliminary model for methotrexate pharmacokinetics. J Pharm Sci 1970;59:149-154.
92. Fisher JW, Whittaker TA, Taylor DH, Clewell H III, Andersen ME. Physiologically based pharmacokinetic modeling of the pregnant rat:a multiroute exposure model for trichloroethylene and its metabolite, trichloroacetic acid. Toxicol Appl Pharmacol 1989;99:395-414.
93. O'Flaherty EJ, Scott W, Schreiner C, Beliles RP. A physiologically based kinetic model of rat and mouse gestation:disposition of a weak acid. Toxicol Appl Pharmacol 1992;112:245-256.
94. Kalin JR, Starling ME, Hill DL. Disposition of all-trans-retinoic acid in mice following oral doses. Drug Metab Dispos 1981;9:196-201.
95. Asai M, Faber W, Neth L, di Sant'Agnese PA, Nakanishi M, Miller RK. Human placental transport and metabolism of all-trans-retinoic acid in vitro. Placenta 1991;12:367-368.
96. Zile MH, Inhorn RC, DeLuca HF. Metabolites of all-trans-retinoic acid in bile:identifi-cation of all-trans-and 13-cis-retinoyl glucuronides. J Biol Chem 1982;257:3537-3543.
97. Swanson BN, Frolik CA, Zaharevitz DW, Roller PP, Sporn MB. Dose-dependent kinetics of all-trans-retinoic acid in rats. Plasma levels and excretion into bile, urine, and faeces. Biochem Pharmacol 1981;30:107-113.
98. Adamson PC, Balis FM, Smith MA, Murphy RF, Godwin KA, Poplack DG. Dose-dependent pharmacokinetics of all-trans-retinoic acid. JNCI 1992;84:1332-1335.
99. Kraft JC, Slikker W Jr, Bailey JR, Roberts LG, Fischer B, Wittfoht W, Nau H. Plasma pharmacokinetic and metabolism of 13-cis-and all-trans-retinoic acid in the cynomolgus monkey and the identification of 13-cis-and all-trans-retinoyl-glucuronides. Drug Metab Dispos 1991;19:317-324.
100. Muindi JRF, Frankel SR, Huselton C, DeGrazia F, Garland WA, Young CW, Warrell RP Jr. Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. Cancer Res 1992;52:2138-2142.
101. Dedrick RL. Pharmacokinetic and pharmacodynamic considerations for chronic hemodialysis. Kidney Int 1975;7(Suppl 2):S7-S15.
102. Rowland M, Balant L, Peck C. Physiologically based pharmacokinetics in drug development and regulatory science:a workshop report(Georgetown University, Washington, DC, 29-30, May 2002). AAPS PharmSci 2004;6(1):E6.
103. Peck CC, Barr WH, Benet LZ, Collins J, Desjardins RE, Furst DE, et al. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. J Pharm Sci 1992;81(6):605-610.
104. Charnick SB, Kawai R, Nedelman JR, Lemaire M, Niederberger W, Sato H. Perspectives in pharmacokinetics. Physiologically based pharmacokinetic modeling as a tool for drug development. J Pharmacokinet Biopharm 1995;23:217-229.
105. Jorgensen WL. The many roles of computation in drug discovery. Science 2004;303(5665):1813-1818.
106. Ricke DO, Wang S, Cai R, Cohen D. Genomic approaches to drug discovery. Curr Opin Chem Biol 2006;10(4):303-308.
107. Lahoz A, Gombau L, Donato MT, Castell JV, Gomez-Lechon MJ. In vitro ADME medium/high-throughput screening in drug preclinical development. Mini Rev Med Chem 2006;6(9):1053-1062.
108. van de Waterbeemd H, Gifford E. ADMET in silico modelling:towards prediction paradise? Nat Rev Drug Discov 2003;2(3):192-204.
109. Blesch KS, Gieschke R, Tsukamoto Y, Reigner BG, Burger HU, Steimer JL. Clinical pharmacokinetic/pharmacodynamic and physiologically based pharmacokinetic modeling in new drug development:the capecitabine experience. Invest New Drugs 2003; 21(2):195-223.
110. Lin JH, Lu AYH. Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev 1997;49:403-449.
111. Lin J, Sahakian DC, de Morais SMF, Xu JJ, Polzer RJ, Winter SM. The role of absorption, distribution, metabolism, excretion and toxicity in drug discovery. Curr Top Med Chem 2003;3:1125-1154.
112. Poulin P, Schoenlein K, Theil FP. Prediction of adipose tissue:plasma partition coeffi-cients for structurally unrelated drugs. J Pharm Sci 2001;90:436-447.
113. Theil FP, Guentert TW, Haddad S, Poulin P. Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection. Toxicol Lett 2003;138:29-49.